Chronic ocular surface disease after allogeneic bone marrow transplantation

Ocular Surface

Volumn 3, Issue 4, 2005, Pages 203-210

  Balaram, Mini ^a,b   Rashid, Saadia ^b,c   Dana, Reza ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Allogeneic bone marrow transplantation; Graft versus host disease; Ocular surface disease

Indexed keywords

ACICLOVIR; ANTIINFLAMMATORY AGENT; ARTIFICIAL TEAR; CORTICOSTEROID; CYCLOSPORIN A; FAMCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE ACETATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TACROLIMUS; THALIDOMIDE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CLINICAL FEATURE; EYE DISEASE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; RETROSPECTIVE STUDY; REVIEW;

EID: 27844523690     PISSN: 15420124     EISSN: 15420124     Source Type: Journal    
DOI: 10.1016/S1542-0124(12)70207-0     Document Type: Article

References (38)

1. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330:827-38
2. Wingard JR, Curbow B, Baker F, Piantadosi S. Health, functional status, and employment of adult survivors of bone marrow transplantation. Ann Intern Med 1991;114:113-8
3. Duell T, van Lint MT, Ljungman P, et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT working party on late effects. European Group for blood and Marrow Transplantation. Ann Intern Med 1997;126:184-92
4. De Marco R, Dassio DA, Vittone P. A retrospective study of ocular side effects of children undergoing bone marrow tansplantation. Eur J Opathamol 1996;6:436-9
5. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989;74:1428-35
6. Hirst LW, Jabs DA, Tutschka PJ, et al. The eye in bone marrow transplantation. I. Clinical study. Arch Ophthalmol 1983;101:580-4
7. Bray LC, Carey PJ, Proctor SJ, et al. Ocular complications of bone marrow transplantation. Br J Ophthalmol 1991;75:611-4
8. Jabs DA, Wingard J, Green WR, et al. The eye in bone marrow transplantation. III. Conjunctival graft-versus-host disease. Arch Ophthalmol 1989;107:1343-8
9. Jack MK, Jack GM, Sale GE, et al. Ocular manifestations of graft-versus-host disease. Arch Ophthalmol 1983;101:1080-4
10. Suh DW, Ruttum MS, Stuckenschneider BJ, et al. Ocular findings after bone marrow transplantation in a pediatric population. Ophthalmology 1999;106:1564-70
11. Franklin RM, Kenyon KR, Tutschka PJ, et al. Ocular manifestations of graft-vs-host disease. Ophthalmology 1983;90:4-13
12. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-304
13. Gratwhol AA, Moutsopoulos HM, Chused TM, et al. Sjogrentype syndrome after allogeneic bone-marrow transplantation. Ann Intern Med 1977;87:703-6
14. Calissendorff B, el Azazi M, Lonnqvist B. Dry eye syndrome in the long-term follow-up of bone marrow transplanted patients. Bone Marrow Transplant 1998;4:675-78
15. Tichelli A, Duell T, Weiss M, et al. Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group fr Blood and Marrow Transplantation (EBMT) Working Party on Late Effects. Bone Marrow Transplant 1996;17:1105-11
16. Cheng LL, Kwok AK, Wat NM, et al. Graft-vs-host-diseaseassociated conjunctival chemosis and central serous chorioretinopathy after bone marrow transplant. Am J Ophthalmol 2002;134:293-5
17. Kiang E, Tesavibul N, Yee R, et al. The use of topical cyclosporin A in ocular gaft-versus-host-disease. Bone Marrow Transplant 1998;22:147-51
18. Rocha EM, Pelegrino FS, de Paiva CS, et al. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant 2000;25:1101-03
19. Ogawa Y, Okamoto S, Kuwana M, et al. Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Cornea 2001;20:430-4
20. Robinson MR, Lee SS, Rubin BI, et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host-disease. Bone Marrow Transplant 2004;33:1031-5
21. Lemp MA. Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes. CLAO J 1995;21:221-32
22. Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after hematopoietic stem cell transplantation. Br J Ophthalmol 1999;83:1125-30
23. Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol 2001;131:30-6
24. West RH, Szer J, Pedersen JS. Ocular surface and lacrimal disturbances in chronic graft-versus-host disease: the role of conjunctival biopsy. Aust N Z J Ophthalmol 1991;19:187-91
25. Dean RM, Bishop MR. Graft-versus-host disease: emerging concepts in prevention and therapy. Curr Hematol Rep 2003;2:287-94
26. Baker KS, Gurney JG, Ness KK, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplantation Survivor Study. Blood 2004;104:1898-906
27. Fraunfelder FT, Meyer SM. Ocular toxicity of antineoplastic agents. Ophthalmology 1983;90:1-3
28. Ogawa Y, Yamazaki K, Kuwana M, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci 2001;42:111-19
29. Juji T, Watanabe Y, Ishikawa Y, et al. Human platelet alloanti-gen (HPA)-5a/b mismatch decreases disease-free survival in unrelated bone marrow transplantation. Tissue Antigens 1999;54:229-34
30. Tseng LH, Lin MT, Hansen JA. et al. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1999;94:2911-4
31. Kim RY, Anderlini P, Naderi AA, et al. Scleritis as the initial clinical manifestation of graft-versus-host disease after allogenic bone marrow transplantation. Am J Ophthalmol 2002;133:843-5
32. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999;106:811-6
33. Balaram M, Dana MR. Phacoemulsification in patients after allogeneic bone marrow transplantation. Ophthalmology 2001;108:1682-7
34. Schwinghammer TI, Bloom EJ. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Clin Pharm 1993;12:736-61
35. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000;96:2062-8
36. Peris-Martinez C, Menezo JL, Diaz Llopis M, et al. Multilayer amniotic membrane transplantation in severe ocular graft versus host disease. Eur J Ophthalmol 2001;11:183-6
37. Kenyon KR, Tseng SC. Limbal autograft transplantation for ocular surface disorders. Ophthalmology 1989;96:709-22; discussion 722-3
38. Heath JD, Acheson JF, Schulenburg WE. Penetrating keratoplasty in severe ocular graft versus host disease. Br J Ophthalmol 1993;77:525-6